Olema Pharmaceuticals reported net income of -$63.69M for the quarter ended Jun 2026. This income statement covers 26 quarters of results from Mar 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Mar2020 | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 39.68M | 39.80M | 39.87M | 39.97M | 40.08M | 40.29M | 40.44M | 41.12M | 44.98M | 45.25M | 55.87M | 57.25M | 57.29M | 58.74M | 85.43M | 68.63M | 68.65M | 81.38M | 87.33M | 87.45M | ||||||
| Operating items | ||||||||||||||||||||||||||
| Research & DevelopmentR&D | 12.52M | 15.97M | 16.01M | 27.05M | 17.63M | 21.58M | 22.83M | 17.99M | 19.45M | 25.87M | 29.88M | 29.11M | 33.23M | 32.30M | 30.62M | 43.90M | 39.95M | 43.22M | 49.23M | 57.78M | ||||||
| Selling, General & AdministrativeSG&A | 5.24M | 5.78M | 7.25M | 6.24M | 5.59M | 5.63M | 6.78M | 3.61M | 3.89M | 4.54M | 4.46M | 4.42M | 4.39M | 4.47M | 4.25M | 3.96M | 5.93M | 6.86M | 8.75M | 9.39M | ||||||
| Operating ExpensesOpex | 17.76M | 21.76M | 23.25M | 33.29M | 23.22M | 27.22M | 29.60M | 21.60M | 23.34M | 30.42M | 34.34M | 33.53M | 37.62M | 36.77M | 34.87M | 47.86M | 45.88M | 50.08M | 57.99M | 67.18M | ||||||
| Operating IncomeOp. Inc | -17.76M | -21.76M | -23.25M | -33.29M | -23.22M | -27.22M | -29.60M | -21.60M | -23.34M | -30.42M | -34.34M | -33.53M | -37.62M | -36.77M | -34.87M | -47.86M | -45.88M | -50.08M | -57.99M | -67.18M | ||||||
| EBIT | -17.76M | -21.76M | -23.25M | -33.29M | -23.22M | -27.22M | -29.60M | -21.60M | -23.34M | -30.42M | -34.34M | -33.53M | -37.62M | -36.77M | -34.87M | -47.86M | -45.88M | -50.08M | -57.99M | -67.18M | ||||||
| Non-operating items | ||||||||||||||||||||||||||
| Non Operating Interest Expenses | ||||||||||||||||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.10M | 0.11M | 0.22M | 0.41M | 0.62M | 0.97M | 1.30M | 1.55M | 1.92M | 3.55M | 3.35M | 3.11M | 2.93M | 3.29M | 4.52M | 4.04M | 3.65M | 4.01M | 4.78M | 4.51M | ||||||
| Other Non Operating IncomeOther Non Op Inc. | -0.06M | 0.01M | 0.01M | 0.02M | -0.12M | 0.07M | 0.01M | -0.04M | -0.08M | 0.09M | 0.02M | 0.04M | 0.14M | -0.09M | -0.04M | 0.04M | 0.01M | 0.01M | 0.12M | -0.53M | ||||||
| Non Operating IncomeNon Op. Inc. | 0.05M | 0.12M | 0.22M | 0.43M | 0.50M | 1.04M | 1.32M | 1.51M | 1.84M | 3.64M | 3.37M | 3.15M | 3.07M | 3.20M | 4.48M | 4.08M | 3.66M | 4.02M | 4.90M | 3.98M | ||||||
| Net income details | ||||||||||||||||||||||||||
| EBT | -17.66M | -21.65M | -23.04M | -32.88M | -22.60M | -26.25M | -28.30M | -20.05M | -21.42M | -26.86M | -30.99M | -30.42M | -34.69M | -33.47M | -30.35M | -43.82M | -42.23M | -46.07M | -53.21M | -62.67M | ||||||
| Profit After TaxPAT | -17.71M | -21.79M | -24.51M | -33.63M | -23.00M | -25.32M | -28.29M | -20.09M | -21.50M | -26.77M | -31.33M | -30.49M | -34.55M | -33.77M | -30.39M | -43.89M | -42.22M | -46.06M | -54.17M | -63.69M | ||||||
| Income from Continuing OperationsIncome (Continuing) | -17.66M | -21.65M | -23.04M | -32.88M | -22.60M | -26.25M | -28.30M | -20.05M | -21.42M | -26.86M | -30.99M | -30.42M | -34.69M | -33.47M | -30.35M | -43.82M | -42.23M | -46.07M | -53.21M | -62.67M | ||||||
| Consolidated Net IncomeConsol Net Inc. | -17.66M | -21.65M | -23.04M | -32.88M | -22.60M | -26.25M | -28.30M | -20.05M | -21.42M | -26.86M | -30.99M | -30.42M | -34.69M | -33.47M | -30.35M | -43.82M | -42.23M | -46.07M | -53.21M | -62.67M | ||||||
| Income towards Parent CompanyParent Net Inc | -17.66M | -21.65M | -23.04M | -32.88M | -22.60M | -26.25M | -28.30M | -20.05M | -21.42M | -26.86M | -30.99M | -30.42M | -34.69M | -33.47M | -30.35M | -43.82M | -42.23M | -46.07M | -53.21M | -62.67M | ||||||
| Preferred Dividend PaymentsPref Dividends | ||||||||||||||||||||||||||
| Net Income towards Common StockholdersNet Income | -17.71M | -21.64M | -23.04M | -32.88M | -22.60M | -26.25M | -28.30M | -20.05M | -21.42M | -26.86M | -30.99M | -30.42M | -34.69M | -33.47M | -30.35M | -43.82M | -42.23M | -46.07M | -53.21M | -62.67M | ||||||
| Additional items | ||||||||||||||||||||||||||
| EPS (Basic) | -0.45 | -0.55 | -0.58 | -0.82 | -0.56 | -0.66 | -0.70 | -0.49 | -0.48 | -0.59 | -0.56 | -0.54 | -0.61 | -0.57 | -0.36 | -0.51 | -0.49 | -0.53 | -0.52 | -0.60 | ||||||
| EPS (Diluted) | -0.45 | -0.55 | -0.58 | -0.82 | -0.56 | -0.66 | -0.70 | -0.49 | -0.48 | -0.59 | -0.56 | -0.54 | -0.61 | -0.57 | -0.36 | -0.51 | -0.49 | -0.53 | -0.52 | -0.60 | ||||||
| Shares Outstanding | 39.61M | 39.52M | 39.83M | 39.92M | 40.04M | 40.00M | 40.35M | 40.72M | 44.98M | 45.25M | 55.57M | 56.28M | 57.26M | 58.74M | 85.43M | 85.50M | 85.73M | 87.01M | 102.80M | 104.45M | ||||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 39.61M | 39.52M | 39.83M | 39.92M | 40.04M | 40.00M | 40.35M | 40.72M | 44.98M | 45.25M | 55.57M | 56.28M | 57.26M | 58.74M | 85.43M | 85.50M | 85.73M | 87.01M | 102.80M | 104.45M | ||||||
| EBITDA | -17.76M | -21.76M | -23.25M | -33.29M | -23.22M | -27.22M | -29.60M | -21.60M | -23.34M | -30.42M | -34.34M | -33.53M | -37.62M | -36.77M | -34.87M | -47.86M | -45.88M | -50.08M | -57.99M | -67.18M | ||||||
| Interest ExpensesInt Expense |